Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 24236794)

1.

Generic atypical antipsychotic drugs in Belgium: their influence and implications.

Godman B, De Bruyn K, Miranda J, Raschi E, Bennie M, Barbui C, Simoens S.

J Comp Eff Res. 2013 Nov;2(6):551-61. doi: 10.2217/cer.13.75.

PMID:
24236794
2.

Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.

Bennie M, Bishop I, Godman B, Barbui C, Raschi E, Campbell S, Miranda J, Gustafsson LL.

Int J Clin Pract. 2013 Feb;67(2):170-80. doi: 10.1111/ijcp.12100.

PMID:
23305478
3.

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, Martin A, Persson M, Piessnegger J, Raschi E, Simoens S, Zara C, Barbui C.

BMC Med. 2014 Jun 13;12:98. doi: 10.1186/1741-7015-12-98.

4.

Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.

Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C, Haycox A.

Appl Health Econ Health Policy. 2011 Mar 1;9(2):101-10. doi: 10.2165/11318840-000000000-00000.

PMID:
21271749
5.

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.

Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmström RE.

Int J Clin Pract. 2013 Sep;67(9):853-62. doi: 10.1111/ijcp.12130. Epub 2013 Apr 8.

PMID:
23560825
6.

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.

Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):469-82. doi: 10.1586/14737167.2013.820956. Review.

PMID:
23977975
7.

Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Godman B, Bucsics A, Burkhardt T, Piessnegger J, Schmitzer M, Barbui C, Raschi E, Bennie M, Gustafsson LL.

Front Pharmacol. 2013 Jan 7;3:198. doi: 10.3389/fphar.2012.00198. eCollection 2012.

8.

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.

Fraeyman J, Van Hal G, Godman B, Beutels P.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):141-51. doi: 10.1586/erp.12.88.

PMID:
23402454
9.

Changes in the utilization of venlafaxine after the introduction of generics in Sweden.

Godman B, Persson M, Miranda J, Skiöld P, Wettermark B, Barbui C, Gustafsson LL.

Appl Health Econ Health Policy. 2013 Aug;11(4):383-93. doi: 10.1007/s40258-013-0037-x.

PMID:
23754677
10.
11.

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.

McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):73-85. doi: 10.1586/erp.09.73.

PMID:
20121565
12.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
13.

Explicit review of risperidone long-acting injection prescribing practice.

Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.

J Clin Pharm Ther. 2011 Dec;36(6):651-63. doi: 10.1111/j.1365-2710.2010.01219.x. Epub 2010 Nov 5.

PMID:
22023342
14.

Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.

Martin A, Godman B, Miranda J, Tilstone J, Saleem N, Olsson E, Acosta A, Restrepo L, Bennie M.

J Comp Eff Res. 2014 Jan;3(1):41-51. doi: 10.2217/cer.13.83.

PMID:
24345256
15.

Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?

Kalaba M, Godman B, Vuksanović A, Bennie M, Malmström RE.

J Comp Eff Res. 2012 Nov;1(6):539-49. doi: 10.2217/cer.12.62.

PMID:
24236473
16.

Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.

Hesse U, Godman B, Petzold M, Martin A, Malmström RE.

Appl Health Econ Health Policy. 2013 Dec;11(6):677-85. doi: 10.1007/s40258-013-0059-4.

PMID:
24105097
17.

Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?

Bennie M, Bishop I, Godman B, Campbell S, Miranda J, Finlayson AE, Gustafsson LL.

Qual Prim Care. 2013;21(1):7-15.

PMID:
23735629
18.

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.

Bucsics A, Godman B, Burkhardt T, Schmitzer M, Malmström RE.

Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):809-19. doi: 10.1586/erp.12.71.

PMID:
23252361
19.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
20.

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.

Woerkom Mv, Piepenbrink H, Godman B, Metz Jd, Campbell S, Bennie M, Eimers M, Gustafsson LL.

J Comp Eff Res. 2012 Nov;1(6):527-38. doi: 10.2217/cer.12.52.

PMID:
24236472
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk